The Irish ABO and Coagulation (iABC) Strategic Partnership

About the Project

This programme will define the biological mechanisms through which ABO blood group influences blood coagulation and thrombosis. Although ABO blood group has been known to affect the risks of bleeding and thrombosis for many years, critically the mechanisms underpinning this relationship remain poorly understood. By bringing together investigators from leading haemostasis research groups in RCSI and blood transfusion medicine experts from the IBTS, the iABC Strategic Partnership will adopt a unique state-of-the-art research programme to characterize the biological mechanisms through which ABO blood group influences blood coagulation. The programme will therefore address clinically important research questions that have key implications for transfusion medicine practice. Given the huge morbidity and mortality associated with bleeding, defining the mechanisms though which ABO affects coagulation is of direct clinical importance. Our innovative plan of investigation will also provide novel insights into the relationship between ABO blood group, heavy menstrual bleeding and iron deficiency in young women.

Supervisors

• Dr. Jamie O'Sullivan
• Prof James O'Donnell

Requirements

• The successful applicant will have a degree (honours bachelors or masters) in a biological sciences subject, such as cell biology, biochemistry, molecular biology, genetics, pharmacology or physiology.
• A strong interest in haematology and vascular biology research
• Good organisational and communication skills.
• Ability to work both independently and as part of a multidisciplinary team

Tenure: 4 year PhD

Applications open: June 29th 2026

Application deadline: July 15th 2026

Shortlisting: Early August

Interviews: Early August (Virtual interviews available)

Planned start date: September 1st 2026